JHL Biotech’s Clinical Trial Application Accepted by China for Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers

JHL Biotech's Clinical Trial Application Accepted by China for Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .

JHL Logo High Resolution (PRNewsFoto/JHL Biotech, Inc.)HSINCHU, Taiwan and WUHAN, China, April 16, 2018 /PRNewswire/ — JHL Biotech announced today that the China Food and Drug Administration (CFDA) has accepted for review JHL’s Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat cancer.
JHL1149 is a…